Commentary: the effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis – authors' reply

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|38|11-12|1406-1407

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.38, Iss.11-12, 2013-12, pp. : 1406-1407

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Commentary: the effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1405-1406

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab in severe ulcerative colitis – is it useful for all patients? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1413-1414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Partial to complete abrogation of the subepithelial macrophage barrier against the gut microbiota in patients with ulcerative colitis and Crohn's colitis

By  

HISTOPATHOLOGY, Vol. 72, Iss. 4, 2018-03 ,pp. : 580-587

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 540-541

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 241-241

John Wiley & Sons Inc

Access to resources Recommend Favorite